Generic Name and Formulations:
Betamethasone (as dipropionate) 0.05%, clotrimazole 1%; crm; lotion.
Merck & Co., Inc.
Indications for LOTRISONE:
Tinea pedis, t. cruris, t. corporis.
T. cruris, t. corporis: apply thin film twice daily for 1 week; max 2 weeks. T. pedis: apply sufficient amount twice daily for 2 weeks; max 4 weeks. Max 45g (crm), 45mL (lotion) per week. Do not occlude.
<17yrs: not recommended.
Avoid eyes. Do not use for diaper dermatitis. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Increased risk of posterior subcapsular cataracts and glaucoma; monitor for visual symptoms. Thinning skin. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Steroid + azole antifungal.
Rash, edema, secondary infections; HPA axis suppression (esp. in children), skin atrophy.
Crm—15g, 45g; Lotion—30mL
Endocrinology Advisor Articles
- Fasting Glycemic Variability Indicates Increased Risk for Type 2 Diabetes
- Heritability of BMI Stronger in Obesogenic Environments
- Domestic Refrigeration May Pose Underestimated Risk for Insulin Quality
- Sitagliptin Provides Better Glycemic Control Than Dapagliflozin in T2D With Renal Impairment
- Adverse Events Associated With Diazoxide Treatment for Congenital Hyperinsulinism
- Causes of Burnout in Resident Physicians Examined
- Thyroid Hormone Therapy Not Beneficial for Subclinical Hypothyroidism
- Bone-Derived Factors in the Treatment of Diabetes
- Bariatric Surgery Reduces Macrovascular Complications in Obesity, T2D
- Without Medicaid Expansion, Poor Patients Forgo Medical Care